Topical Drug Delivery Industry 2024 by Worldwide Market Size, Product Type, End User, Key Vendors, Growth Rate, Drivers, Volume & Forecast Report

Global Topical Drug Delivery Market is expected to reach USD 205.1 billion by 2024 from USD 101.7 billion in 2016, growing at a CAGR of 9.2% in the forecast period 2017 to 2024. The new market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.

Request for Sample Report Visit @ http://databridgemarketresearch.com/request-a-sample/?dbmr=global-topical-drug-delivery-market

Market Segmentation:

The Global Topical Drug Delivery Market is segmented on the basis of product type, indication, distribution channel, end user and geography.

On the basis of product type the market is segmented into transdermal drug delivery devices and topical drug delivery formulations. Topical drug delivery formulations are further segmented based on form into solid, semi-solid and liquid. The semi solid segment is further classified into ointments, creams, lotions, gels and pastes. The solid drugs segment is further segmented into powders and suppositories. The liquid drugs segment is further classified into solutions and suspensions. The transdermal drug delivery devices market segment is further segmented into patches and gels.

The topical drug delivery market is segmented on the basis of indications into 4 types such as acne, anesthetics, psoriasis, dermatitis & atopic dermatitis, rosacea, onychomycosis, alopecia, actinic keratosis, and others. In 2017, anti-acne is expected to dominate the market with the highest market share in the forecast period 2017 to 2024.

On the basis of end users the market is segmented into hospitals, home healthcare, clinics, diagnostic centers, and others. In 2017, the hospitals segment is expected to dominate the global topical drug delivery devices market with more than 40% market share.

Based on geography the market is segmented into 5 geographical regions, North America, Europe, Asia-Pacific, South America and rest of the world. The geographical regions are further segmented into 24 major countries such as U.S. Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Turkey, Japan, China, Singapore, Brazil, India, Russia, South Africa and many others.

Inquiry Before Buying @ http://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-topical-drug-delivery-market

Key Players Analysis:

The global topical drug delivery market is highly concentrated to a few big players and rest to local players who cater to domestic markets only. Galderma Pharma, S.A., dominated the topical drug delivery market accounting for a highest market share in 2016, followed by Bayer AG, and Valeant Pharmaceuticals. Other players in this market include Allergen Plc. Kaken Pharmaceuticals, Co., Ltd, Pfizer, 3M, Hisamitsu Pharmaceuticals, Co., Inc., Abbvie, Inc., Antares Pharma among others. Some of the other players in the global topical drug delivery market are MedPharm, Janssen Pharmaceuticals, Inc. (A J&J Company), Crescita Therapeutics, West Pharmaceutical Services, Biofarmitalia s.r.l, Pharmatek Laboratories, Inc., Stiefel Laboratories, Inc., Tapemark, Acrux Limited, Nitto Denko Corporation, Skinvisible Pharmaceuticals, Inc., Mylan Pharmaceuticals Inc., Pocono Coated Products LLC, TheraSolve NV., Samyang Biopharmaceuticals Corporation, Lohmann Therapie-Systeme AG, Prosollus Pharmaceuticals, Easton Pharmaceuticals Inc., Novosis AG, Endo Pharmaceuticals Inc., Transdermal Technologies, Inc., Sheffield Pharmaceuticals, Inc., and Solvay among others.

Galderma Pharma S.A.

Galderma Pharma S.A. was incorporated in 1981, as a joint between Nestle and L'Oreal. In February, 2014 Nestle SA, entered into an agreement to acquire remaining 50% stake in the company, from L'Oreal S.A. After the completion of the acquisition the company will form the foundation of Nestle Skin Health S.A. Galderma Pharma S.A. is headquartered in Lausanne Switzerland.

Recent developments:

1. In July 2016, Galderma announces fda approval of full prescription-strength differin gel for over-the-counter acne use.

2. In July 2016, Galderma announces approval of epiduo gel for the treatment of acne in Japan.

Bayer AG

Founded in 1863 and headquartered in Leverkusen, Germany, Bayer AG is a provider of healthcare, nutrition, and high-technology materials and services. The company has three business segments, namely, HealthCare, Crop Science, and Material Science.

Recent Developments:

1. On July 2015, the U.S. Food and Drug Administration (FDA) approved Finacea Foam, for the topical treatment of the inflammatory papules and pustules of mild to moderate rosacea.

Valeant Pharmaceuticals International, Inc.

Founded in 1994 and headquartered in Quebec, Canada, Valeant Pharmaceuticals International, Inc. is a pharmaceutical company which engages in developing, manufacturing, and marketing pharmaceutical products in the areas of dermatology, eye health, neurology, and generics.

Recent Developments;

1. In August 2016, Valeant announced the re-launch of its generic ofloxacin otic solution to treat bacterial ear infections. The product was temporarily discontinued in April 2015 due to an issue concerning the active pharmaceutical ingredient supplier, which has been resolved.

Read more about the Global Topical Drug Delivery Market @ http://databridgemarketresearch.com/reports/global-topical-drug-delivery-market/

Table of Contents:

1. INTRODUCTION

1.1. OVERVIEW OF GLOBAL TOPICAL DRUG DELIVERY MARKET
1.2. CURRENCY AND PRICING
1.3. LIMITATION
1.4. MARKETS COVERED

2. MARKET SEGMENTATION

2.1. MARKETS COVERED
2.2. GEOGRAPHIC SCOPE
2.3. YEARS CONSIDERED FOR THE STUDY
2.4. CURRENCY AND PRICING
2.5. RESEARCH METHODOLOGY
2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7. SECONDARY SOURCES
2.8. ASSUMPTIONS

3. MARKET OVERVIEW

3.1. DRIVERS

3.1.1. RISING CASES OF ACUTE AND CHRONIC DISEASE
3.1.2. RISING AGING POPULATION
3.1.3. TECHNOLOGICAL ADVANCEMENTS AND INNOVATIONS
3.1.4. APPROVAL OF NEW DRUGS
3.1.5. BETTER OPPORTUNITY IN PHARMERGING MARKETS

3.2. RESTRAINTS

3.2.1. REGULATORY SCENARIO AND PRICING PRESSURE

3.3. OPPORTUNITY

3.3.1. ENERGING MARKET
3.3.2. RISING ACCEPTANCE FOR SELF-ADMINISTRATION OF DRUGS

3.4. CHALLENGES

3.4.1. PRODUCT RECALL
3.4.2. PENETRATION INTO THE SMALLER MARKETS

4. PREMIUM INSIGHTS

5. EXECUTIVE SUMMARY

6. GLOBAL TOPICAL DRUG DELIVERY MARKET, BY TYPE

6.1. OVERVIEW

6.2. TRANSDERMAL DRUG DELIVERY SYSTEMS (TDDS)
6.3. TOPICAL DRUG FORMULATION, BY PRODUCT TYPE
6.4. LIQUID TOPICAL DRUG FORMULATION, BY PRODUCT TYPE
6.5. SEMI SOLID TOPICAL DRUG FORMULATION, BY PRODUCT TYPE
6.6. SOLID TOPICAL DRUG FORMULATION, BY PRODUCT TYPE

7. GLOBAL TOPICAL DRUG DELIVERY MARKET, BY INDICATION

7.1. OVERVIEW
7.2. GLOBAL TOPICAL DRUG DELIVERY MARKET, BY INDICATION
7.3. GLOBAL ANTI-INFECTIVE TOPICAL DRUG DELIVERY MARKET, BY INDICATION

8. GLOBAL TOPICAL DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL

8.1. OVERVIEW
8.2. GLOBAL TOPICAL DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL

9. GLOBAL TOPICAL DRUG DELIVERY MARKET, BY END USER

9.1. OVERVIEW

10. GLOBAL TOPICAL DRUG DELIVERY MARKET, BY GEOGRAPHY

10.1. OVERVIEW

10.2. NORTH AMERICA TOPICAL DRUG DELIVERY MARKET

10.2.1. U.S. TOPICAL DRUG DELIVERY MARKET
10.2.2. CANADA TOPICAL DRUG DELIVERY MARKET
10.2.3. MEXICO TOPICAL DRUG DELIVERY MARKET

10.3. EUROPE TOPICAL DRUG DELIVERY MARKET

10.3.1. GERMANY TOPICAL DRUG DELIVERY MARKET
10.3.2. FRANCE TOPICAL DRUG DELIVERY MARKET
10.3.3. ITALY TOPICAL DRUG DELIVERY MARKET
10.3.4. U.K. TOPICAL DRUG DELIVERY MARKET
10.3.5. SWITZERLAND TOPICAL DRUG DELIVERY MARKET
10.3.6. SPAIN TOPICAL DRUG DELIVERY MARKET
10.3.7. NETHERLAND TOPICAL DRUG DELIVERY MARKET
10.3.8. RUSSIA TOPICAL DRUG DELIVERY MARKET
10.3.9. TURKEY TOPICAL DRUG DELIVERY MARKET
10.3.10. BELGIUM TOPICAL DRUG DELIVERY MARKET
10.3.11. REST OF EUROPE TOPICAL DRUG DELIVERY MARKET

10.4. APAC TOPICAL DRUG DELIVERY MARKET

10.4.1. JAPAN TOPICAL DRUG DELIVERY MARKET
10.4.2. CHINA TOPICAL DRUG DELIVERY MARKET
10.4.3. SOUTH KOREA TOPICAL DRUG DELIVERY MARKET
10.4.4. INDIA TOPICAL DRUG DELIVERY MARKET
10.4.5. AUSTRALIA TOPICAL DRUG DELIVERY MARKET
10.4.6. SINGAPORE TOPICAL DRUG DELIVERY MARKET
10.4.7. THAILAND TOPICAL DRUG DELIVERY MARKET
10.4.8. MALAYSIA TOPICAL DRUG DELIVERY MARKET
10.4.9. INDONESIA TOPICAL DRUG DELIVERY MARKET
10.4.10. PHILIPPINES TOPICAL DRUG DELIVERY MARKET
10.4.11. REST OF APAC TOPICAL DRUG DELIVERY MARKET

10.5. SOUTH AMERICA TOPICAL DRUG DELIVERY MARKET

10.5.1. BRAZIL TOPICAL DRUG DELIVERY MARKET
10.5.2. REST OF SOUTH AMERICA TOPICAL DRUG DELIVERY MARKET

10.6. MIDDLE EAST AND AFRICA (MEA) TOPICAL DRUG DELIVERY MARKET

10.6.1. SOUTH AFRICA TOPICAL DRUG DELIVERY MARKET
10.6.2. REST OF MEA TOPICAL DRUG DELIVERY MARKET

11. GLOBAL TOPICAL DRUG DELIVERY MARKET, COMPANY SHARE

11.1. COMPANY SHARE ANALYSIS: GLOBAL

12. COMPANY PROFILES

12.1. GALDERMA PHARMA S.A.

12.1.1. COMPANY OVERVIEW
12.1.2. FINANCIAL OVERVIEW
12.1.3. PRODUCT PORTFOLIO
12.1.4. RECENT DEVELOPMENTS

12.2. HISAMITSU PHARMACEUTICAL CO., INC.

12.2.1. COMPANY OVERVIEW
12.2.2. REVENUE ANALYSIS
12.2.3. PRODUCT PORTFOLIO
12.2.4. RECENT DEVELOPMENTS

12.3. PFIZER INC.

12.3.1. COMPANY OVERVIEW
12.3.2. REVENUE ANALYSIS
12.3.3. PRODUCT PORTFOLIO
12.3.4. RECENT DEVELOPMENTS

12.4. ABBVIE INC.

12.4.1. COMPANY OVERVIEW
12.4.2. REVENUE ANALYSIS
12.4.3. PRODUCT PORTFOLIO
12.4.4. RECENT DEVELOPMENTS

12.5. BAYER AG

12.5.1. COMPANY OVERVIEW
12.5.2. REVENUE ANALYSIS
12.5.3. PRODUCT PORTFOLIO
12.5.4. RECENT DEVELOPMENTS

12.6. 3M

12.6.1. COMPANY OVERVIEW
12.6.2. REVENUE ANALYSIS
12.6.3. PRODUCT PORTFOLIO
12.6.4. RECENT DEVELOPMENTS

12.7. ANTARES PHARMA, INC.

12.7.1. COMPANY OVERVIEW
12.7.2. REVENUE ANALYSIS
12.7.3. PRODUCT PORTFOLIO
12.7.4. RECENT DEVELOPMENTS

12.8. VALEANT PHARMACEUTICALS INTERNATIONAL, INC.

12.8.1. COMPANY OVERVIEW
12.8.2. REVENUE ANALYSIS
12.8.3. PRODUCT PORTFOLIO
12.8.4. RECENT DEVELOPMENTS

12.9. ALLERGAN PLC.

12.9.1. COMPANY OVERVIEW
12.9.2. REVENUE ANALYSIS
12.9.3. PRODUCT PORTFOLIO
12.9.4. RECENT DEVELOPMENTS

12.10. KAKEN PHARMACEUTICALS CO., LTD

12.10.1. COMPANY OVERVIEW
12.10.2. REVENUE ANALYSIS
12.10.3. PRODUCT PORTFOLIO

Related Report

Global Tumor Ablation Market – Industry Trends and Forecast to 2024

Global Tumor Ablation market By Type (Tumor Ablation Systems {Radio Frequency Ablation System, Microwave Ablation System, Cryoablation, High Intensity Focused Ultrasound , Laser Ablation System}, Image Guidance Products, Accessories), By Cancer Type (Liver Cancer, Brain Cancer, Lung Cancer, Bone Cancer, Kidney Cancer, Pancreatic Cancer, Breast Cancer, Others), By Mode of Treatment (Surgical, Laparoscopic, Percutaneous), By End User (Hospitals, Oncology Clinics, Others), By Region (North America, Europe, Asia Pacific, South America, Middle East and Africa)– Industry Trends and Forecast to 2024

Report Access: http://databridgemarketresearch.com/reports/global-tumour-ablation-market/

About Data Bridge Market Research:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:
Vishal Dixit
Data Bridge Market Research
Tel: +1-888-387-2818
Email: Sales@databridgemarketresearch.com

This release was published on openPR.